News & Events about Senti Biosciences Inc.
R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors SENTI-202 on track for IND filing in 2H 2023 Cash runway guidance extended through ...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (Senti Bio), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, Co-founder and Chief ...
ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies SENTI-202 is on track for IND filing ...
Globe Newswire
2 months ago
Review of new preclinical data and clinical development plan for SENTI-202 in hematologic malignancies; also featuring KOL discussion of treatment landscape and unmet need in AML Live and webcast event on Sunday, December 11, 11:30 am - 12:30 pm CST SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE ...
Globe Newswire
3 months ago
Poster presentation to highlight preclinical data for SENTI-202 which employs Logic Gating gene circuit technology in off-the-shelf CAR-NK cells designed to more precisely target CD33 and/or FLT3 expressing AML cell lines while protecting healthy cellsSOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (...